Tango Therapeutics Inc
TNGX
Company Profile
Business description
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Contact
201 Brookline Avenue
Suite 901
BostonMA02215
USAT: +1 857 320-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
155
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 7.50 | -0.08% |
| CAC 40 | 8,152.12 | 83.50 | 1.03% |
| DAX 40 | 24,281.60 | 95.11 | 0.39% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,740.77 | 91.74 | 0.95% |
| HKSE | 25,628.88 | 347.91 | -1.34% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 50,168.11 | 668.44 | -1.31% |
| NZX 50 Index | 13,408.14 | 1.23 | 0.01% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,635.00 | 8.90 | -0.10% |
| SSE Composite Index | 3,867.92 | 21.42 | -0.55% |